1. Medtech Insight
  2. >>Policy & Regulation

Q&A: Renalytix AI Prez Explains How MCIT Rule Will Aid Kidney Product Coverage By CMS

 
• By Sue Darcey

Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.

Kidney disease. 3d illustration.
3D Illustration of kidney disease, the risk for which can be diagnosed through use of Renalytix AI’s new KidneyIntelX artificial intelligence-enabled diagnostic

Release of the final Medicare Coverage of Innovative Technology (MCIT) rule by the US Centers for Medicare and Medicaid Services (CMS) means Renalytix AI’s KidneyIntelX artificial intelligence-enabled in vitro diagnostic platform may be launched soon, company president Tom McLain told Medtech Insight in a 19 January interview.

Released by the CMS on 12 January, the MCIT rule allows instant reimbursement for US Food and Drug Administration breakthrough...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

EU Pilot Features ‘All-In-One’ Regulatory Path For Drug/Diagnostic Trials

 
• By Vibha Sharma

The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.

European Medtechs Reiterate Opposition To Reciprocal Tariffs On US Imports

 
• By Ashley Yeo

EU countermeasures against US tariffs suggest medtech categories exported to the EU could be targeted for tariffs. MedTech Europe and the German IVDs industry have stressed the negative effects this would have on patient care.

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 
• By Natasha Barrow

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.